Moderator: Lisa Ponssa, EVP, Healthcare Business Media
Presenters: Bonnie Kirschenbaum, Consultant and Columnist and Steven Schnelle, Associate, McDermott, Will & Emery
After years of public outrage, an increasing wave of proposals addressing drug pricing have emerged at both the state and the national levels throughout 2019. While the end goal is to lower the costs for payor, provider and patient through greater pricing transparency and more efficient distribution models, these complex proposed changes will have far reaching implications for in and out patient hospital operations.
This session first will dive into the pricing proposals in play and include discussions of the Prescription Drug Pricing Reduction Act of 2019 and The Safe Importation Action Plan among others. A discussion of the implications of proposed 2020 OPPS and PFS payment rules (among others) then follows. The proposed rules also have taken a strong stance on transparency as well as clearly defining reimbursement strategy in a site neutral manner. There won't be any margins to manage without an understanding of the rule sets and changes in strategy!
1. Define the potential impact new pricing proposals and rules have on Medicare, Medicaid reimbursement for hospital pharmacy operations.
2. Differentiate the components of the various proposals and rules impacting IDN pharmacy operations.
3. Analyze the importance of IDN specific analytics when preparing for these proposals and rules that will impact your pharmacy supply chain.